RecruitingNCT06353191
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity
Sponsor
Mayo Clinic
Enrollment
1,000 participants
Start Date
May 3, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Non-Interventional Study for people with hematopoietic and lymphatic system neoplasm and malignant solid neoplasm. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06353191
Related Trials
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276188 locations
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
NCT075350081 location
Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
NCT072355011 location
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
NCT060134231 location
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT0569149123 locations